Loading organizations...
Amani Therapeutics is a New York-based biotechnology company developing novel therapeutic solutions and highly efficacious medicines specifically targeted toward treating severe psychiatric illnesses. The enterprise focuses on acquiring and advancing promising drug candidates through strategic licensing agreements with established pharmaceutical corporations to address significant unmet clinical needs in mental health care. For its lead clinical development program, designated as AM-01, the organization successfully in-licensed a Phase 3-ready novel chemical entity directly from AstraZeneca. Operating under a traditional venture-backed biopharmaceutical business model, the firm has raised $25 million in total funding to support its ongoing clinical trials and broader research initiatives. This initial capital was secured primarily through the financial backing of lead institutional investor RTW Investments, which provided the necessary resources to accelerate the commercialization timeline of their acquired therapeutic assets. Amani Therapeutics was founded in 2025.
Amani Therapeutics has raised $25.0M across 1 funding round.
Amani Therapeutics has raised $25.0M in total across 1 funding round.
Amani Therapeutics has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2026 | $25M Series A | RTW Investments | — | Announced |
Amani Therapeutics has raised $25.0M in total across 1 funding round.
Amani Therapeutics's investors include RTW Investments.
